All right. Good morning, everyone. Good morning, everyone. Thank you for joining. My name is Faisal Khurshid. I am one of the Senior Biotech Analysts here at Jefferies. We are here in nice, rainy London at the Jefferies Global Healthcare Conference. Really pleased to have this morning management team at Monte Rosa Therapeutics. That is GLUE, I love your stock ticker. Markus Warmuth is on stage with me. Markus, can I ask you to kick it off, give us some opening remarks?
Yeah. First of all, thanks for having us here at this conference. Always excited to be here in London. Just a few words on Monte Rosa Therapeutics. For those who are not familiar, we are doing targeted protein degradation. We are doing it in a very special way, a modality that we like to call molecular glue degraders. These are small molecules. They are true small molecules. They bind to what is called a ubiquitin ligase that is part of the cell intrinsic protein degradation pathway. They bind to these ubiquitin ligases and essentially reshape their surface to create now a novel protein-protein interaction surface. This is a way to get rid of proteins in a very, very selective way. This has been a constant theme throughout our portfolio, exquisite selectivity, and obviously, that creates really safe molecules.
We are applying this across multiple disease areas, and I am pretty sure we are talking a lot about the existing public portfolio.
Got it. Let us start with your NEK7 degrader, MRT-8102. Can you maybe just, let us start with sort of the concept and idea of NEK7 and where it can go, because there are a few different areas across the indications that you have chosen for phase II, and each have very different kind of development considerations. So, we will talk about that, but maybe just to start, what is this molecule and why does it have this breadth of applicability?
Yeah. We are now in inflammatory diseases, trying to target the NLRP3 pathway. This is an inflammasome that is mostly responsible for what we call sterile inflammation. It is not as much engaged in host defense. It is really more trying to deal with anything that is intrinsic metabolites, and this is essentially how we are sort of positioning the molecule, at least for now, like all sorts of inflammatory conditions, gout, ASCVD, HS, driven by either crystals of metabolites or oxidized versions of metabolites. I have mentioned some of the indications. We have prioritized, obviously, ASCVD really remains a focus for us, despite, as some of you know, some of the challenges post-Novo failure around the IL-6 antibody. The first phase II, though, that is now initiating is in gout, and again, very good validation for that indication around the NLRP3 pathway.
Got it. Across your three indications that you have chosen for phase II, you have ASCVD, you have gout, you have HS. Can you talk to us about how you see the risk profile across the three? If I were to ask you to force rank them from highest probability of success to least, how do you think about that?
Yeah, I mean, it is a great question. It is a little bit like asking me who my favorite child is.
Yeah.
Also, that is-
Sorry
-an easier answer because I only have two and not three.
That makes it easy.
But honestly, I mean, we like all indications, right? I mean, let's go back to why we picked them. Very strong validation, clinical and preclinical validation for the NLRP3 inflammasome driving at least inflammation and pain in these diseases. We spent a lot of time looking at publicly available data sets for what's the level of pathway activation, NLRP3 pathway activation. Between that and existing proof of concepts, gout, ASCVD, and HS rose to the top. You could argue that gout at this point maybe has the least risk. Gout in general as an indication does fly a little bit under the radar, so some of that data isn't as well known as, for example, ZEUS' failure. There are now novel IL-1β antibodies out of China, just recently added to the proof of concept for the pathway in gout.
And so, all things considered, and also looking at sort of the size and the ease of conducting that phase II trial, maybe the lowest risk, but you never know until you know. We really still are very confident around ASCVD. I've referenced that infamous, now infamous ZEUS trial quite a bit by now. This was Novo's attempt to improve outcome, cardiovascular outcome in ASCVD using an IL-6 antibody. Didn't go so well. I think we now do understand why the trial failed. It is really a combination of IL-6 not being a good target, probably their antibody not being the best antibody to neutralize IL-6, because we now know after they've published the data that the antibody left around 20%-25% IL-6 on the table. So, it's not a complete inhibition of the pathway, although their CRP decreases in a way suggested it would be.
There's clearly too much IL-6 left in the system, and there were clearly also flaws in the trial design, meaning too many comorbidities that likely influenced how modifiable the cardiovascular risk of those patients was. We do think all of this can be addressed in our program. We're going to go after the pathway fairly upstream, and certainly the trial design eventually will look very different from what Novo did.
Got it. I want to talk about gout, because you mentioned you're starting the GEMINI-1 study, I believe shortly here. Can you talk about the trial design? I believe you said that you will be able to show some initial data next year. What should we be looking for in that dataset?
Yeah, so, this is a fairly simple trial design. GEMINI-1, we're actually looking at prevention of gout flares after managing an acute flare. So this will be patients that we like to call frequent flare-ers. So they do have a couple of flares per year, if not more. They will go on the trial as they have the first flare. So, we'll start therapy at that point, and then obviously the important readout will be after that first flare on the trial has been managed, can we prevent additional flares? Because that's really what's important in gout, right? I think there's a lot of talk now about urate-lowering drugs. They only help so and so much, and quite honestly, patients care only so and so much because they do not care about their urate levels.
They care about, "Do I have another very painful flare or not?" So we do think that at the end of the day, flare prevention, if that works out, is the better market. So it's a relatively small trial, two dose levels, open-label expansion. We often get the question around placebo control. We really do think placebo controls are important. In this case, though, it doesn't make sense, because I would either have to tell a patient that they have to suck up the pain for 72 hours or more, or offer them rescue medicine, which is of course what you do, and then when you offer rescue medicine, obviously it's not really a true placebo control anymore. That said, I referenced the IL-1β antibodies that have emerged recently in China.
Other agents in the pathway that have been tested before, there is enough historical data to know when our data will be good and meaningful.
Got it. With respect to, you are doing a single arm, or not single arm, but no placebo control study looking at a flare reduction. How do you think about at least controlling the patient population so that you do not have a regression to the mean or placebo-like effect? How do we make sure that this is an interpretable readout here?
Yeah, again, this is sort of looking back into what are the historical flare rates in that setting. Probably over a three to six months time period, around 50%-60% in a non-treated population. As you basically cut this down, again, you can look at some of the IL-1β antibodies, those reductions were quite significant. You basically know that you have something that is successful.
Got it. Then in terms of a reduction in flare rate or the percent of flare-ers, what kind of benchmark would you point to? What do you say would be encouraging to see and support further development?
Yeah, again, I'm always cautious with numbers, right? Because at the end of the day, it depends a little bit on what's the population you're eventually recruiting, how frequently have they flared before, what are the comorbidities? You definitely at least want to cut the rate, I've referenced 50%-60%, in half to be meaningful.
Got it. Okay. That makes sense. When should we expect that study to kick off, and can you talk about your level of confidence in ability to recruit the study in a timely manner?
Yeah, the guidance actually for initiating that trial is this quarter, so it's on track. Obviously confident that this trial will recruit in a very timely fashion. Guidance for data readout will be, or is second half of next year.
Great. Excellent. I want to talk about HS next.
So, we recently saw, or at least top-line data from AbbVie for lutikizumab in HS. That is an IL-1 drug, so obviously a little bit different from what you are doing. That data, it came in a bit below the data that we saw in phase II that I think people would agree is exciting. I know we just have the top line, but given this data, how are you thinking about the IL-1, NEK7, inflammasome hypothesis in HS at this point?
Yeah, we definitely think that hypothesis is still very strong, and honestly, this kind of goes beyond the current phase III readout. I think the scientific support from expression profiles for this pathway being a main driver stands and is extremely strong. I think the issue we have seen in HS over the last couple of years is not an NLRP3 pathway-specific one, right? I think we have had molecules in the IL-17 arena that did not perform quite as well as expected. Like AbbVie's lutikizumab now did not perform as expected based on their original phase II results. There was a recent readout on an IL-17, IL-18 bispecific did not come in as expected, and it is typically a combination of two things, right? The efficacy arm not working out as great as expected, but also, of course, placebo now more and more frequently over-performing.
I think it is certainly something we have an eye on, talking a lot with our KOLs about. It is hopefully something that the entire field will start to have a handle on. But certainly, coming back to your question on sort of risk, certainly for that indication creates some risk. We are sort of anxiously awaiting now Novartis' readout on remibrutinib, right? So you have another modality in the pathway now, a small molecule. It will be interesting to see how placebo came in for them, and then from there, hopefully, we can sort of sit down and derive our conclusions on how to best handle that in our trial.
Got it. That makes sense. I want to talk about ASCVD. You said you are still very confident in ASCVD. Can you talk about the measures that you have put into the phase II study? I think have been pretty thoughtful to run a nice study here. Can you talk about the design of that and what you have done from, I think the two things I thought were pretty notable were the patient selection and the imaging component of the study as well.
Yeah, absolutely. I mean, again, back to why, where is this confidence coming from? I mean, you look into existing data, again, clinical and preclinical. This is a fairly pure NLRP3 pathway play. It goes from elevated lipids, oxidized, stimulating the NLRP3 pathway in atherosclerotic plaques, and then obviously from there causing harm. There aren't as many other pathways involved here as compared to, for example, HS, right? Where we've now talked about Th17.
Right
B cells and the NLRP3 pathway. ASCVD, I always call like a pure play NLRP3 indication. How are we trying to address this in our phase II study? Obviously, a lot learned from ZEUS and now the more detailed data rollout in our phase II, which will be a six-month study across three dose levels. We're not just using blood biomarkers to determine whether there is an inflammatory risk left. We're also using imaging. The imaging field has progressed very nicely. There's a new imaging method, or analysis method, I should say, called FAI, Fat Attenuation Index, that has been linked to cardiovascular risk. Very nice study that was published in Lancet where individuals, patients with elevated FAI scores had really tremendously increased cardiovascular risk to a point where I think in the upper quartile, it was elevated 30-fold. That's whopping, right? So mortality in that quartile was increased 30-fold.
We're using that to not select patients yet. It's not a selection process, but to determine what the FAI score is, how that correlates to CRP. We're obviously trying to avoid comorbidities like CKD, which can be confounding because any form of kidney inflammation obviously on its own leads to a lot of CRP, so systemic inflammation. We believe combined, we will get a much cleaner readout around ASCVD, obviously, as you know, with a focus on coronary artery disease in our case.
Got it. I want to shift gears. I want to talk about your VAV1 degrader.
That is partnered with Novartis. Novartis has started a couple of phase II studies in Sjögren's and psoriatic arthritis that has generated some nice collaboration revenue for you guys. I know you are limited on how much you can say in terms of indication selection, timelines, things like that. Could you at least just at a high level help investors understand the breadth of applicability for VAV1, and just approximately how many indications we should expect this development plan to kind of look like?
Happy to. As you pointed out, there are limited things I can say about the program now that it is partnered with Novartis. I will start by saying we are super happy with that collaboration. It is a great interaction. Those of you who know us know we have an office in Switzerland, in Basel, that is literally across the Rhine from Novartis' campus. That interaction is fairly easy. Whenever I am there, I can just walk across-
Yeah
-the bridge and talk to my partners there. The program is really off to a good start. Two phase II trials that have initiated, those are integrated phase IIa/b studies, fairly large size. We are talking hundreds of patients per trial. Those trials are in Sjögren's disease and psoriatic arthritis. In general, and it is fair to say that we have done a lot of work, Novartis likely did a whole lot more work on VAV1 than we. They liked the target for years even before we were founded. In general, everywhere where you have an autoimmune disease that is driven by T cells or the interplay of T cells with B cells is where you could go. Preclinically, we have done studies in Sjögren's disease, and it was really good to see that that indication kicked off. We have done preclinical studies in rheumatoid arthritis.
That is an indication that would make a ton of sense based on our data. We have worked through several models in the IBD, could make a ton of sense. We are not short of ideas here. I think between Novartis and Monte Rosa, we have extremely tight alignment on vitiligo. Yes, clearly fair to say that everyone should be expecting several more trials to kick off.
Got it. Okay. Several more. That is good to hear. I know there was a lot of investors were getting a little bit restless when we did not see the phase IIs start. I remember you were saying, "Just be patient. They are doing a big program here." It makes sense.
Yeah. No, right. I always say, look, it is going to be a big program, and that just takes a little bit more preparation than just doing a 40-patient, more typical phase IIa before you decide what else to do. I think you are now seeing the fruits of taking a little bit longer.
Yeah, totally. Can I just ask you to briefly talk about the competitive landscape in VAV1? I think it is interesting that we recently saw Evommune do a licensing deal for an asset that, at least just based on the press release, it is described as a VAV1 molecular glue degrader. At least high level, the same type of thing to what you are doing. I know there are other small molecule approaches out there as well. How are you seeing this space?
Yeah. In general, I think that is what is helpful for us around molecular glue degraders. The IP space tends to be much narrower than, let us say, for kinase inhibitors, or other types of modalities. We are obviously aware that there are Chinese companies trying to now do VAV1 MGD. I feel kind of honored that they felt inspired to follow us. We do think we are in pretty good shape. I think we left very few, if any, IP gaps around good chemical space. It does not mean that there is not chemical space, it is just not good chemical space. I also think we did the right thing on VAV1 to partner with Novartis, which again, as we talked about, is pursuing this at a scale that is going to give us such a head start overall vis-à-vis competition that I am absolutely not concerned about it.
Got it. Then, I know this Novartis partnership has been very nice for this asset in particular, given the breadth of applicability. As you think broader across your portfolio, both for the assets that you have in the clinic as well as the discovery engine, I think you call it the QuEEN engine, how are you thinking about partnerships and collaborations going forward?
Yeah. I think the good news is, our engine, call it QuEEN, is extremely productive. It's probably more productive than we need to for our own purposes, which of course gives us opportunities to continue to do meaningful partnerships. We obviously have a very decent runway at this point. Guidance is into 2029, so I think there's not an urgency to do additional partnerships, but we've always been fairly pragmatic about it. Sometimes say strategically non-strategic, which is not the right expression, but we're not sitting down at the beginning of the year and like, "We want to partner molecule A and B and not C and D." We're typically more looking, "Okay, what asset does now make sense to partner?" Because you can now develop it much broader.
VAV1 fit that criteria, and we decided to do, but we're also keen to have assets wholly owned in our portfolio and actually grow our wholly owned portfolio over time as well.
Got it. Then, as you think about NEK7, right? I could make the argument to you that NEK7 could be equally broad or even broader than where VAV1 could go, given that you have these kind of big medical problems of ASCVD, gout, inflammatory disease that you can tackle. How do you think about partnership potential around the NEK7 specifically?
Yeah. I'd say not too dissimilar from what I just said. Right now, we do really, really want to own it, hang onto it. We think gout's a great opportunity. It's fairly self-developable, how we like to sort of call it. ASCVD, at the end of the day, could be more challenging. Also, we do think that when you hone in into this sort of imaging-based subpopulation in CAD with remaining inflammatory risk, the trial might actually not be as big as people think. We're thinking it could be more in the 2,000 patient range, to be determined, right, once we have GFORCE-2, and I think we can sort of take it from there. As you know, we also have at least one additional molecule lined up, which again opens up for partnerships that are eventually maybe more indication-specific.
I think all optionality here on the table, and we'll make decisions as we go.
Got it. Great. Well, thank you so much, Markus, for being here. I think we're just about at time. I just wanted to close with, as we kind of get into the next year, what do you kind of ask investors to focus on more?
Yeah. I think obviously exciting year coming up, right? We're now with, very soon, three assets in phase II. As I mentioned, VAV1 program growing. Probably no data next year, but I think you'll be fairly impressed sort of seeing how this continues to evolve. Clearly, the important readouts next year to focus on will be gout for MRT-8102. And sure, it'll be interesting to see how the entire ASCVD field sort of recovers from the ZEUS shock. I think it'll be great, and hopefully more positivity there next year as well.